<DOC>
	<DOCNO>NCT02716181</DOCNO>
	<brief_summary>A Double-Blind Randomized Placebo-Controlled Trial Evaluate Efficacy `` Атопик Soothing Cream '' Children Mild Moderate Atopic Dermatitis</brief_summary>
	<brief_title>Efficacy `` Атопик Soothing Cream '' Children With Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description>`` Атопик Soothing Cream '' lipid complex compose barley grain , Butyrospermum Parkii Argania Spinosa Kernel oil , mixture panthenol bisabolol . Investigators concure combination substance `` Атопик Soothing Cream '' efficacious non-steroidal treatment Atopic Dermatiti ( AD ) .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Must clinical diagnosis mild moderate atopic dermatitis ( AD ) Screening Baseline Visits , define IGA score 2 3 ( Rothe 1996 ) EASI score 2 21 ( Leshem 2015 ) Must AD affect &gt; 5 % total body surface area ( TBSA ) Baseline History AD least 3 month prior Baseline Informed consent/assent accordance International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) Guideline applicable regulation , complete studyrelated procedure Use topical corticosteroid within 7 day prior Baseline Use systemic corticosteroid , topical calcineurin inhibitor , phototherapy ( PUVA , UVB ) immunosuppressive therapy ( eg , cyclosporine ) within 14 day prior Baseline Subjects require systemic therapy treatment AD Use systemic antiinfective antibiotic treatment within 14 day prior Baseline Subjects present clinical condition AD may interfere evaluation ( eg , generalized erythroderma , acne , Netherton 's Syndrome , psoriasis ) Any clinically significant skin disease AD Secondary infection AD ( bacterial , viral fungal ) within skin area study open skin infection area Baseline History severe anxiety and/or depression ; history suicide attempt Subjects history human immunodeficiency virus ( HIV ) determine medical history Subjects , opinion Investigator ( ) , would noncompliant visit schedule study procedure Participation investigational trial within 6 week Baseline , study conduct Chronic condition ( ) either unstable adequately control Drug alcohol abuse , mental dysfunction , condition limit subject 's ability compliant studyrelated procedure Any medical condition may , opinion Investigator ( ) , preclude safe administration test article safe participation study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Topical therapy</keyword>
</DOC>